Latest news
Enterprise value to EBITDA forward of Noxopharm Ltd. – ASX:NOX - TradingViewTradingView · Wed, 05 Aug 2026 05:38:15 GMTNoxopharm Unveils Preclinical Evidence That TLR8-Enhancing Oligonucleotides Activate Immune Response to Normally Silent Cancer RNA - Kalkine MediaKalkine Media · Tue, 04 Aug 2026 03:54:05 GMTNoxopharm Reports Preclinical Data Showing TLR8-Amplifying Oligonucleotides Override Immune-Silent Cancer RNA - KalkineKalkine · Tue, 04 Aug 2026 03:54:05 GMTNoxopharm study strengthens prospects for immune activating cancer treatment - BiotechDispatchBiotechDispatch · Tue, 04 Aug 2026 00:14:52 GMTNoxopharm Data Validate TLR8-Targeted Oligonucleotide Cancer Strategy - TipRanksTipRanks · Mon, 03 Aug 2026 23:30:24 GMT